tiprankstipranks
LivaNova PLC (LIVN)
NASDAQ:LIVN
US Market
Want to see LIVN full AI Analyst Report?

LivaNova (LIVN) Stock Forecast & Price Target

280 Followers
See the Price Targets and Ratings of:

LIVN Analyst Ratings

Strong Buy
8Ratings
Strong Buy
6 Buy
2 Hold
0 Sell
Based on 8 analysts giving stock ratings to
LivaNova
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LIVN Stock 12 Month Forecast

Average Price Target

$85.63
▲(9.51% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for LivaNova in the last 3 months. The average price target is $85.63 with a high forecast of $95.00 and a low forecast of $76.00. The average price target represents a 9.51% change from the last price of $78.19.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"$40","54":"$54","68":"$68","82":"$82","96":"$96"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$85.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$76.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,54,68,82,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.14,81.28307692307692,82.42615384615385,83.56923076923077,84.71230769230769,85.85538461538462,86.99846153846154,88.14153846153846,89.28461538461539,90.42769230769231,91.57076923076923,92.71384615384616,93.85692307692308,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.14,80.56192307692308,80.98384615384616,81.40576923076924,81.8276923076923,82.24961538461538,82.67153846153846,83.09346153846154,83.51538461538462,83.9373076923077,84.35923076923078,84.78115384615384,85.20307692307692,{"y":85.625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.14,79.82153846153847,79.50307692307692,79.18461538461538,78.86615384615385,78.5476923076923,78.22923076923077,77.91076923076923,77.5923076923077,77.27384615384615,76.95538461538462,76.63692307692308,76.31846153846153,{"y":76,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.63,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.11,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.53,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.27,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.63,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.81,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.48,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.14,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$95.00Average Price Target$85.63Lowest Price Target$76.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham
$81$93
Buy
18.94%
Upside
Reiterated
08/05/26
LivaNova price target raised to $93 from $81 at NeedhamLivaNova price target raised to $93 from $81 at Needham
Stifel Nicolaus Analyst forecast on LIVN
Stifel Nicolaus
Stifel Nicolaus
$80$85
Buy
8.71%
Upside
Reiterated
08/05/26
LivaNova price target raised to $85 from $80 at StifelLivaNova price target raised to $85 from $80 at Stifel
Mizuho Securities Analyst forecast on LIVN
Mizuho Securities
Mizuho Securities
$90$95
Buy
21.50%
Upside
Reiterated
07/15/26
LivaNova price target raised to $95 from $90 at MizuhoLivaNova price target raised to $95 from $90 at Mizuho
Freedom Capital Markets Analyst forecast on LIVN
Freedom Capital Markets
Freedom Capital Markets
$81
Hold
3.59%
Upside
Initiated
06/30/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: LivaNova (NASDAQ: LIVN), Gain Therapeutics (NASDAQ: GANX) and Tempus AI, Inc. Class A (NASDAQ: TEM)
Piper Sandler Analyst forecast on LIVN
Piper Sandler
Piper Sandler
$87
Buy
11.27%
Upside
Reiterated
06/23/26
Piper Sandler Reaffirms Their Buy Rating on LivaNova (LIVN)
KeyBanc
$83$92
Buy
17.66%
Upside
Assigned
06/22/26
LivaNova (LIVN) Gets a Buy from KeyBanc
Robert W. Baird Analyst forecast on LIVN
Robert W. Baird
Robert W. Baird
$78$76
Buy
-2.80%
Downside
Reiterated
05/07/26
LivaNova price target lowered to $76 from $78 at BairdLivaNova price target lowered to $76 from $78 at Baird
Barclays Analyst forecast on LIVN
Barclays
Barclays
$73$76
Hold
-2.80%
Downside
Reiterated
05/07/26
Barclays Keeps Their Hold Rating on LivaNova (LIVN)
Goldman Sachs Analyst forecast on LIVN
Goldman Sachs
Goldman Sachs
$70$72
Hold
-7.92%
Downside
Reiterated
05/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Revolution Medicines (NASDAQ: RVMD), LivaNova (NASDAQ: LIVN) and Vir Biotechnology (NASDAQ: VIR)
Jefferies
$79$80
Buy
2.31%
Upside
Reiterated
08/07/25
Jefferies Sticks to Their Buy Rating for LivaNova (LIVN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham
$81$93
Buy
18.94%
Upside
Reiterated
08/05/26
LivaNova price target raised to $93 from $81 at NeedhamLivaNova price target raised to $93 from $81 at Needham
Stifel Nicolaus Analyst forecast on LIVN
Stifel Nicolaus
Stifel Nicolaus
$80$85
Buy
8.71%
Upside
Reiterated
08/05/26
LivaNova price target raised to $85 from $80 at StifelLivaNova price target raised to $85 from $80 at Stifel
Mizuho Securities Analyst forecast on LIVN
Mizuho Securities
Mizuho Securities
$90$95
Buy
21.50%
Upside
Reiterated
07/15/26
LivaNova price target raised to $95 from $90 at MizuhoLivaNova price target raised to $95 from $90 at Mizuho
Freedom Capital Markets Analyst forecast on LIVN
Freedom Capital Markets
Freedom Capital Markets
$81
Hold
3.59%
Upside
Initiated
06/30/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: LivaNova (NASDAQ: LIVN), Gain Therapeutics (NASDAQ: GANX) and Tempus AI, Inc. Class A (NASDAQ: TEM)
Piper Sandler Analyst forecast on LIVN
Piper Sandler
Piper Sandler
$87
Buy
11.27%
Upside
Reiterated
06/23/26
Piper Sandler Reaffirms Their Buy Rating on LivaNova (LIVN)
KeyBanc
$83$92
Buy
17.66%
Upside
Assigned
06/22/26
LivaNova (LIVN) Gets a Buy from KeyBanc
Robert W. Baird Analyst forecast on LIVN
Robert W. Baird
Robert W. Baird
$78$76
Buy
-2.80%
Downside
Reiterated
05/07/26
LivaNova price target lowered to $76 from $78 at BairdLivaNova price target lowered to $76 from $78 at Baird
Barclays Analyst forecast on LIVN
Barclays
Barclays
$73$76
Hold
-2.80%
Downside
Reiterated
05/07/26
Barclays Keeps Their Hold Rating on LivaNova (LIVN)
Goldman Sachs Analyst forecast on LIVN
Goldman Sachs
Goldman Sachs
$70$72
Hold
-7.92%
Downside
Reiterated
05/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Revolution Medicines (NASDAQ: RVMD), LivaNova (NASDAQ: LIVN) and Vir Biotechnology (NASDAQ: VIR)
Jefferies
$79$80
Buy
2.31%
Upside
Reiterated
08/07/25
Jefferies Sticks to Their Buy Rating for LivaNova (LIVN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
TNYATenaya Therapeutics
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering LivaNova

3 Months
David RescottRobert W. Baird
Success Rate
8/11 ratings generated profit
73%
Average Return
+11.87%
Copying David Rescott's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +11.87% per trade.
1 Year
David RescottRobert W. Baird
Success Rate
11/11 ratings generated profit
100%
Average Return
+49.14%
Copying David Rescott's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +49.14% per trade.
2 Years
David RescottRobert W. Baird
Success Rate
11/11 ratings generated profit
100%
Average Return
+73.06%
Copying David Rescott's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +73.06% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LIVN Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
7
5
6
6
5
Hold
2
2
3
3
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
7
9
9
6
In the current month, LIVN has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. LIVN average Analyst price target in the past 3 months is 85.63.
Each month's total comprises the sum of three months' worth of ratings.

LIVN Financial Forecast

LIVN Earnings Forecast

Next quarter’s earnings estimate for LIVN is $1.05 with a range of $1.02 to $1.11. The previous quarter’s EPS was $1.26. LIVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year LIVN has Performed in-line its overall industry.
Next quarter’s earnings estimate for LIVN is $1.05 with a range of $1.02 to $1.11. The previous quarter’s EPS was $1.26. LIVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year LIVN has Performed in-line its overall industry.

LIVN Sales Forecast

Next quarter’s sales forecast for LIVN is $380.44M with a range of $378.00M to $385.78M. The previous quarter’s sales results were $390.59M. LIVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year LIVN has Performed in-line its overall industry.
Next quarter’s sales forecast for LIVN is $380.44M with a range of $378.00M to $385.78M. The previous quarter’s sales results were $390.59M. LIVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year LIVN has Performed in-line its overall industry.

LIVN Stock Forecast FAQ

What is LIVN’s average 12-month price target, according to analysts?
Based on analyst ratings, LivaNova PLC’s 12-month average price target is 85.63.
    What is LIVN’s upside potential, based on the analysts’ average price target?
    LivaNova PLC has 9.51% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is LIVN a Buy, Sell or Hold?
          LivaNova PLC has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.
            What is LivaNova PLC’s price target?
            The average price target for LivaNova PLC is 85.63. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $95.00 ,the lowest forecast is $76.00. The average price target represents 9.51% Increase from the current price of $78.19.
              What do analysts say about LivaNova PLC?
              LivaNova PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of LIVN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.